-- Companies continue broad program to develop investigational Aurora kinase inhibitors as novel treatments for a range of cancers -- -- Merck to initiate clinical development of VX-689 --
Cambridge, MA, November 5, 2007 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentations at the 9th Annual MASS Opportunities Investment Conference on Thursday, November 8, 2007 at 2:45 p.m.
Two Large Phase 2 Trials of Telaprevir, an Investigational Hepatitis C Protease Inhibitor, Dosed in Combination with Pegylated Interferon and Ribavirin Show SVR Rates of 61% and 65% Initial Rapid Viral Decline Appears Important to Achieve SVR Safety Profile Consistent with Prior Interim Analyses
Vertex Pharmaceuticals Reports Third Quarter 2007 Financial Results and Provides Development Pipeline Update Important telaprevir data to be presented at AASLD Additional compounds for HCV and Cystic Fibrosis scheduled to enter development Cambridge, MA, October 29, 2007 Vertex
CAMBRIDGE, Mass., Oct 09, 2007 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will announce its third quarter 2007 financial results on Monday, October 29, 2007 after the financial markets close. The Company will host a conference call at 5:00 p.m. EDT.
-- Conference Presentations to Include Data from Two Randomized, Controlled Phase 2 Clinical Studies of Investigational HCV Protease Inhibitor Telaprevir --
CAMBRIDGE, Mass., Sep 14, 2007 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentations at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference on Tuesday, September 18th at 1:00 p.m. GMT (8:00 a.m.
CAMBRIDGE, Mass., Sep 05, 2007 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the Bear Stearns 20th Annual Healthcare Conference on Monday, September 10th at 3:00 p.m. EDT.
CAMBRIDGE, Mass., Jul 24, 2007 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the quarter ended June 30, 2007, and the Company provided a pipeline update. "Vertex achieved its major development pipeline milestones in the first
CAMBRIDGE, Mass., Jul 09, 2007 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will announce its second quarter 2007 financial results on Tuesday, July 24, 2007 after the financial markets close. The Company will host a conference call at 5:00 p.m. EDT.
